

| | Baseline | After 6-month treatment with liraglutide | P |
|------------------------------|-------------|--|--------------|
| VLDL₁ | | | |
| • Esterified Cholesterol (%) | 6.1 ± 2.2 | 7.6 ± 4.4 | 0.61 |
| • Free Cholesterol (%) | 6.5 ± 0.9 | 4.6 ± 1.7 | 0.021 |
| • Triglycerides (%) | 64.3 ± 5.3 | 66.4 ± 5.1 | 0.64 |
| • Phospholipids (%) | 15.5 ± 3.7 | 15.0 ± 1.4 | 0.87 |
| • Proteins (%) | 7.6 ± 2.1 | 6.4 ± 0.9 | 0.20 |
| • EC/TG ratio | 0.10 ± 0.04 | 0.12 ± 0.08 | 0.57 |
| VLDL₂ | | | |
| • Esterified Cholesterol (%) | 14.9 ± 3.2 | 17.6 ± 4.9 | 0.13 |
| • Free Cholesterol (%) | 7.6 ± 0.8 | 7.0 ± 1.6 | 0.57 |
| • Triglycerides (%) | 48.2 ± 4.7 | 45.2 ± 6.8 | 0.11 |
| • Phospholipids (%) | 17.4 ± 2.2 | 19.3 ± 1.9 | 0.09 |
| • Proteins (%) | 11.7 ± 3.8 | 10.8 ± 1.9 | 0.76 |
| • EC/TG ratio | 0.31 ± 0.1 | 0.41 ± 0.16 | 0.037 |
| IDL | | | |
| • Esterified Cholesterol (%) | 29.5 ± 3.8 | 32.1 ± 3.8 | 0.028 |
| • Free Cholesterol (%) | 9.1 ± 0.8 | 9.3 ± 2.2 | 0.44 |
| • Triglycerides (%) | 26.9 ± 5.5 | 22.1 ± 6.8 | 0.015 |
| • Phospholipids (%) | 19.7 ± 1.7 | 22.2 ± 2.2 | 0.028 |
| • Proteins (%) | 14.6 ± 2.0 | 14.3 ± 2.1 | 0.75 |
| • EC/TG ratio | 1.15 ± 0.3 | 1.59 ± 0.3 | 0.009 |
| LDL | | | |
| • Esterified Cholesterol (%) | 44.6 ± 2.0 | 43.5 ± 2.9 | 0.14 |
| • Free Cholesterol (%) | 8.9 ± 0.7 | 9.3 ± 0.7 | 0.28 |
| • Triglycerides (%) | 7.6 ± 1.3 | 7.6 ± 2.1 | 0.79 |
| • Phospholipids (%) | 20.4 ± 1.9 | 22.4 ± 1.2 | 0.022 |
| • Proteins (%) | 18.4 ± 0.9 | 17.2 ± 1.5 | 0.047 |
| • EC/TG ratio | 6.06 ± 1.1 | 6.12 ± 1.6 | 0.64 |

Supplementary Table 2: ApoB100-containing lipoprotein composition in patients before and after 6-month treatment with liraglutide. Data are expressed as mean ± SD. EC: Esterified Cholesterol. TG: Triglycerides